Solid Biosciences (SLDB) Capital Leases (2018 - 2024)

Solid Biosciences has reported Capital Leases for 7 years, with the latest figure at $307000.0 in Q3 2024.

• Quarterly Capital Leases fell 77.46% year-over-year to $307000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $307000.0 (down 77.46% YoY) and the FY2023 annual result came in at $1.2 million, down 27.54% from the prior year.
• Capital Leases declined to $307000.0 in Q3 2024 per SLDB's latest filing, from $953000.0 in the prior quarter.
• Over five years, Capital Leases peaked at $1.7 million in Q4 2022 and troughed at $231000.0 in Q1 2022.
• A 5-year average of $818470.6 and a median of $632000.0 in 2020 frame the typical range for Capital Leases.
• The sharpest annual moves came in 2023 and 2024: Capital Leases surged 590.91% in 2023, then slumped 77.46% in 2024.
• Over 5 years, Capital Leases stood at $525000.0 in 2020, then slumped by 44.19% to $293000.0 in 2021, then soared by 481.23% to $1.7 million in 2022, then slipped by 27.54% to $1.2 million in 2023, then slumped by 75.12% to $307000.0 in 2024.
• According to Business Quant data, Capital Leases over the past three periods registered $307000.0, $953000.0, and $1.1 million for Q3 2024, Q2 2024, and Q1 2024 respectively.